Evidence map›Paper›PMID 34784010›Full record

ArticleHuman cell2022

Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma.

Zhanqiang Liang, Xingxing Li, Fei Duan, Liming Song, Zhongzhen Wang, Xuemin Li, Pengsheng Yang, Liantao Li

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Overview of miR-106a Regulatory Roles: from Cancer to Aging.Bioengineering (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhanqiang LiangDepartment of Hepatobiliary Surgery, Zhengzhou Central Hospital Affiliated To Zhengzhou University, Zhengzhou, 450007, Henan, China.
Xingxing LiDepartment of General Surgery, Xinzheng Public People's Hospital, Xinzheng, Zhengzhou, 451150, Henan, China.
Fei DuanDepartment of Hepatobiliary Surgery, Zhengzhou Central Hospital Affiliated To Zhengzhou University, Zhengzhou, 450007, Henan, China.
Liming SongDepartment of Hepatobiliary Surgery, Zhengzhou Central Hospital Affiliated To Zhengzhou University, Zhengzhou, 450007, Henan, China.
Zhongzhen WangDepartment of General Surgery, Xinzheng Public People's Hospital, Xinzheng, Zhengzhou, 451150, Henan, China.
Xuemin LiDepartment of Hepatobiliary Surgery, Zhengzhou Central Hospital Affiliated To Zhengzhou University, Zhengzhou, 450007, Henan, China.
Pengsheng YangDepartment of Hepatobiliary Surgery, Zhengzhou Central Hospital Affiliated To Zhengzhou University, Zhengzhou, 450007, Henan, China.
Liantao LiDepartment of General Surgery, Xinzheng Public People's Hospital, Xinzheng, Zhengzhou, 451150, Henan, China. jio262352@163.com.ORCID http://orcid.org/0000-0001-6631-0245
Zhengzhou Central Hospital · CNZhengzhou People's Hospital · CN

Funding

Joint Construction Project of Henan Medical Science and Technology Project 2018020811
6 · The paper itself

Abstract

Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is abnormally expressed in many human cancers. However, its role in hepatocellular carcinoma (HCC) is indeterminate. In this study, immunohistochemistry and Western blot were adopted to detect PTPN12 protein expression in HCC tissues and cell lines. MiR-106a-5p and PTPN12 mRNA expressions were determined by quantitative real-time polymerase chain reaction (qRT-PCR). siRNA was used to knockdown PTPN12 expression in HCC cells, and the multiplication, migration, and invasion of HCC cells were determined by cell counting kit 8 (CCK-8) and Transwell assays. The interaction between PTPN12 and miR-106a-5p was verified by dual-luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay. In the present study, we demonstrated that PTPN12 expression in HCC tissues and cells was significantly decreased, which was associated with the tumor size, TNM stage, and lymph node metastasis of HCC patients. Functionally, knocking down PTPN12 significantly promoted the multiplication, migration, invasion, and epithelial-mesenchymal transition (EMT) of HCC cells. PTPN12 was identified as the direct target of miR-106a-5p, and its expression was negatively modulated by miR-106a-5p. Besides, PTPN12 counteracted the promoting effects of miR-106a-5p on the viability, migration, invasion, and EMT of HCC cells. In conclusion, this study substantiates that PTPN12 inhibits the growth, migration, invasion, and EMT of HCC cells, and miR-106a-5p contributes to its dysregulation in HCC.

Indexed as

Carcinoma, HepatocellularCell Line, TumorCell MovementCell SurvivalDisease ProgressionEpithelial-Mesenchymal TransitionGene ExpressionGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMicroRNAsNeoplasm InvasivenessProtein Tyrosine Phosphatase, Non-Receptor Type 12MicroRNAsMIRN106 microRNA, humanProtein Tyrosine Phosphatase, Non-Receptor Type 12PTPN12 protein, humanHCCInvasionMigrationMiR-106a-5pPTPN12Viability

Identifiers

PMID34784010
OpenAlexW3213043292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.